Initial surgical management of squamous carcinoma of the vulva

被引:0
作者
Salazar-Baez, Israel [1 ]
Salazar-Campos, Jessica E. [1 ]
Lopez-Arias, Alhely [2 ]
Villavicencio-Valencia, Veronica [3 ]
Coronel-Martinez, Jaime [3 ]
Candelaria-Hernandez, Myrna [3 ]
Perez-Montiel, Delia [4 ]
Perez-Plasencia, Carlos [3 ]
Elizabeth Rojas-Garcia, Aurora [5 ]
Cantu de Leon, David [2 ]
机构
[1] Inst Nacl Cancerol INCan, Dept Ginecol & Oncol, Mexico City, DF, Mexico
[2] Inst Nacl Cancerol INCan, Subdirecc Invest Clin, Ave San Fernando 22,Col Secc 16, Mexico City 14000, DF, Mexico
[3] Inst Nacl Cancerol INCan, Direcc Invest, Mexico City, DF, Mexico
[4] Inst Nacl Cancerol INCan, Dept Patol, Mexico City, DF, Mexico
[5] Univ Autonoma Nayarit, Secretaria Invest & Posgrad, Mexico City, DF, Mexico
来源
GACETA MEDICA DE MEXICO | 2016年 / 152卷 / 03期
关键词
Cancer; Vulva; Stage; Carcinoma; Squamous; Survival; RECURRENCE; CANCER;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Vulvar cancer accounts for approximately 4% of gynecological malignancies. At the Instituto Nacional de Cancerologia in Mexico it occupies the fourth place. The purpose of this study is to assess the management of squamous carcinoma of the vulva with initial surgical treatment. It is a descriptive retrospective, observational study, from January 1, 2002 to December 31, 2012. Twenty-seven patients, clinical stages I, II, or III, initial surgical management, with at least one year of follow-up were included. In 51.85% a partial vulvectomy was performed and in 40.74% a wide excision; 66.66% underwent inguinofemoral dissection. Recurrence occurred in 25.91% of cases and the overall survival at 10 years was 63%. It is concluded that with invasion of up to 1 mm of lymph node, affection is 0%; with invasion of 1 mm and up to 5 mm this increases to 25%; an invasion of more than 5 mm implies up to 45%. Recurrence in our study was primarily distant, necessitating long-term monitoring with emphasis on symptoms to request imaging studies when suspected. Adjuvant therapy should be offered to patients with positive nodes, close or positive margins, and tumors larger than 4 cm.
引用
收藏
页码:297 / 303
页数:7
相关论文
共 23 条
[1]   LYMPHOSCINTIGRAPHY IN VULVAR CANCER - A PILOT-STUDY [J].
BARTON, DPJ ;
BERMAN, C ;
CAVANAGH, D ;
ROBERTS, WS ;
HOFFMAN, MS ;
FIORICA, JV ;
FINAN, MA .
GYNECOLOGIC ONCOLOGY, 1992, 46 (03) :341-344
[2]   Single agent cisplatin chemotherapy in surgically resected vulvar cancer patients with multiple inguinal lymph node metastases [J].
Bellati, F ;
Angioli, R ;
Manci, N ;
Zullo, MA ;
Muzii, L ;
Plotti, F ;
Basile, S ;
Panici, PB .
GYNECOLOGIC ONCOLOGY, 2005, 96 (01) :227-231
[3]  
Bosque OJ, 2008, REV CUBANA CIR, V47, P4
[4]   A Thirty-year Review of Vulvar Cancer in Jamaica, 1978 to 2007 [J].
Bromfield, M. E. ;
Gibson, T. N. ;
Hanchard, B. ;
Waugh, N. ;
McNaughton, D. .
WEST INDIAN MEDICAL JOURNAL, 2014, 63 (02) :134-137
[5]   THE IMPORTANCE OF THE GROIN NODE STATUS FOR THE SURVIVAL OF T1 AND T2 VULVAR CARCINOMA PATIENTS [J].
BURGER, MPM ;
HOLLEMA, H ;
EMANUELS, AG ;
KRANS, M ;
PRAS, E ;
BOUMA, J .
GYNECOLOGIC ONCOLOGY, 1995, 57 (03) :327-334
[6]   The treatment of lateral T1 and T2 squamous cell carcinomas of the vulva confined to the labium majus or minus [J].
DeSimone, Christopher P. ;
Van Ness, Jennifer S. ;
Cooper, Amy L. ;
Modesitt, Susan C. ;
DePriest, Paul D. ;
Ueland, Frederick R. ;
Pavlik, Edward J. ;
Kryscio, Richard J. ;
van Nagell, John R., Jr. .
GYNECOLOGIC ONCOLOGY, 2007, 104 (02) :390-395
[7]   CONSERVATIVE AND INDIVIDUALIZED SURGERY FOR EARLY SQUAMOUS CARCINOMA OF THE VULVA - THE TREATMENT OF CHOICE FOR STAGE-I AND II (T1-2N0-1M0) DISEASE [J].
FARIASEISNER, R ;
CIRISANO, FD ;
GROUSE, D ;
LEUCHTER, RS ;
KARLAN, BY ;
LAGASSE, LD ;
BEREK, JS .
GYNECOLOGIC ONCOLOGY, 1994, 53 (01) :55-58
[8]   SURGICAL-PATHOLOGICAL VARIABLES PREDICTIVE OF LOCAL RECURRENCE IN SQUAMOUS-CELL CARCINOMA OF THE VULVA [J].
HEAPS, JM ;
FU, YS ;
MONTZ, FJ ;
HACKER, NF ;
BEREK, JS .
GYNECOLOGIC ONCOLOGY, 1990, 38 (03) :309-314
[9]  
I.R.C.P, 2012, GYN CANC PORTF AN SU
[10]  
Maggino T, 2000, CANCER-AM CANCER SOC, V89, P116, DOI 10.1002/1097-0142(20000701)89:1<116::AID-CNCR16>3.0.CO